RedHill Biopharma Ltd., a foreign private issuer, has announced an Extraordinary General Meeting of Shareholders to be held on March 20, 2024. The primary agenda for the meeting is to seek shareholder approval for an increase in the company's authorized share capital. The meeting will take place at the company's offices in Tel Aviv, Israel. Shareholders of record as of February 19, 2024, are entitled to vote at the meeting. The Board of Directors has recommended a vote in favor of the proposal. The company has also made provisions for shareholders to submit written statements regarding their position on the agenda item by March 10, 2024. The proposal, if passed, would amend the company's Articles of Association to increase the authorized share capital...Show More

RedHill Biopharma Ltd., a foreign private issuer, has announced an Extraordinary General Meeting of Shareholders to be held on March 20, 2024. The primary agenda for the meeting is to seek shareholder approval for an increase in the company's authorized share capital. The meeting will take place at the company's offices in Tel Aviv, Israel. Shareholders of record as of February 19, 2024, are entitled to vote at the meeting. The Board of Directors has recommended a vote in favor of the proposal. The company has also made provisions for shareholders to submit written statements regarding their position on the agenda item by March 10, 2024. The proposal, if passed, would amend the company's Articles of Association to increase the authorized share capital from NIS 200,000,000 to NIS 400,000,000. This increase would provide RedHill with the flexibility to issue additional shares for corporate purposes, including fundraising and strategic transactions. The Board believes this is necessary to avoid potential delays and expenses that could arise from seeking special stockholder approval for each issuance opportunity. The company's filings, including this notice and proxy statement, are available on the SEC's website and the company's website.